Format
Sort by

Send to

Choose Destination

Search results

Items: 20

1.

Passive smoking and smoking cessation among patients with coronary heart disease across Europe: results from the EUROASPIRE III survey.

Prugger C, Wellmann J, Heidrich J, De Bacquer D, Perier MC, Empana JP, Reiner Ž, Fras Z, Jennings C, Kotseva K, Wood D, Keil U; EUROASPIRE Study Group.

Eur Heart J. 2014 Mar;35(9):590-8. doi: 10.1093/eurheartj/eht538. Epub 2013 Dec 13.

2.

Residual risk of cardiovascular mortality in patients with coronary heart disease: the EUROASPIRE risk categories.

De Bacquer D, Dallongeville J, Kotseva K, Cooney MT, Pajak A, Deckers JW, Mayer O, Vanuzzo D, Lehto S, Fras Z, Östor E, Ambrosio GB, De Backer G, Wood D, Keil U, Sans S, Graham I, Pyörälä K.

Int J Cardiol. 2013 Sep 30;168(2):910-4. doi: 10.1016/j.ijcard.2012.10.051. Epub 2012 Nov 14.

PMID:
23157810
3.

Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey.

Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio GB, Reiner Z, Gaita D, Wood D, Kotseva K, Heidrich J; EUROASPIRE III Study Group.

J Hypertens. 2011 Aug;29(8):1641-8. doi: 10.1097/HJH.0b013e328348efa7.

PMID:
21720270
4.

[Data on secondary prevention of coronary artery disease in Hungary and some changes in the last ten years (EUROASPIRE 1995-2005)].

Jánosi A, Ostör E, Borbás S, Kazinczy R, Káli A, Vámos I, Bradák A, Podmaniczky M.

Orv Hetil. 2010 Oct 24;151(43):1776-82. doi: 10.1556/OH.2010.28961. Hungarian.

PMID:
20940117
5.

EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Reiner Z, Keil U; EUROASPIRE Study Group.

Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):530-40. doi: 10.1097/HJR.0b013e3283383f30.

PMID:
20577089
6.

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM; ATLAS ACS-TIMI 46 study group.

Lancet. 2009 Jul 4;374(9683):29-38. doi: 10.1016/S0140-6736(09)60738-8. Epub 2009 Jun 17.

PMID:
19539361
7.

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group.

Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):121-37. doi: 10.1097/HJR.0b013e3283294b1d.

PMID:
19287307
8.

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group.

Lancet. 2009 Mar 14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-5.

PMID:
19286092
9.

Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction.

Mega JL, Morrow DA, Ostör E, Dorobantu M, Qin J, Antman EM, Braunwald E.

Circulation. 2007 Jun 5;115(22):2822-8. Epub 2007 May 21.

10.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators.

Lancet. 2005 Oct 8;366(9493):1279-89.

PMID:
16214598
11.

Effective control of hypertension: a project of the Hungarian Society of Hypertension, baseline data.

Farsang C, Alföldi S, Barna I, Finta PE, Kapocsi J, Kishegyi J, Kiss I, Lamm G, Ostör E, Tamás F.

J Hum Hypertens. 2004 Aug;18(8):591-4.

PMID:
15002002
12.

[Secondary prevention of coronary disease--at the turn of the millennium in light of the Hungarian data of the EUROASPIRE I-II. Studies].

Ostör E, Jánosi A, Adám Z, Bárczy G, Borbás S, Dávid B, Gallai I, Podmaniczky M, Ruzsányi T.

Orv Hetil. 2003 Dec 7;144(49):2399-404. Hungarian.

PMID:
14725205
13.

Overweight and obesity in patients with established coronary heart disease: are we meeting the challenge?

De Bacquer D, De Backer G, Cokkinos D, Keil U, Montaye M, Ostör E, Pyörälä K, Sans S.

Eur Heart J. 2004 Jan;25(2):121-8.

14.

Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort.

De Bacquer D, De Backer G, Ostör E, Simon J, Pyörälä K; EUROASPIRE I Study Group.

Eur J Cardiovasc Prev Rehabil. 2003 Aug;10(4):289-95.

PMID:
14555885
15.

[EUROASPIRE: survey conducted by the European Society of Cardiology on secondary prevention of coronary disease. Hungarian results].

Ostör E, Jánosi A, Belatiny KA, Borbás S, Bradak A, Podmaniczky M.

Orv Hetil. 1999 Jan 31;140(5):243-8. Hungarian.

PMID:
10064978
16.

Risk factors for coronary heart disease in rural Hungary.

Lamm G, Csukás M, Gyárfás J, Ostör E.

Int J Epidemiol. 1985 Jun;14(2):327-9.

PMID:
4019001
17.

Electrocardiographic findings and their association with mortality in the Copenhagen City Heart Study.

Ostör E, Schnohr P, Jensen G, Nyboe J, Hansen AT.

Eur Heart J. 1981 Aug;2(4):317-28. No abstract available.

PMID:
7297572
18.

[Transient myocardial damage caused by smallpox revaccination].

Bodor G, Binder L, Ostör E.

Orv Hetil. 1973 May 6;114(18):1060-2. Hungarian. No abstract available.

PMID:
4697968
19.

Effect of Nuredal on angina pectoris.

Ostör E.

Ther Hung. 1968;16(3):121-2. No abstract available.

PMID:
5726084
20.

Prevention of the cardiotoxic effect of quinidine by isoproterenol.

GOTTSEGEN G, OSTOR E.

Am Heart J. 1963 Jan;65:102-9. No abstract available.

PMID:
13949513
Items per page

Supplemental Content

Loading ...
Write to the Help Desk